Kappos L, et al. - During this study, authors inspected the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor_1,5 modulator, on disability progression in patients (aged 18–60 years) with secondary progressive multiple sclerosis (SPMS). A reduction was achieved in the risk of disability progression due to siponimod. Siponimod demonstrated a safety profile similar to that of other S1P modulators and appeared to be a beneficial treatment for SPMS.